论文部分内容阅读
目的探讨肺癌患者服用扶正升白汤治疗化疗后白细胞减少的临床疗效。方法 50例肺癌患者,随机分为观察组和对照组,各25例。对照组采用利血生片治疗,观察组服用扶正升白汤治疗,比较两组患者治疗后的临床疗效。结果治疗前,观察组患者的白细胞计数为(6.55±1.89)×109/L,治疗后2周为(5.28±1.52)×109/L;对照组分别为(6.47±1.82)、(4.75±1.10)×109/L;两组患者治疗前白细胞计数比较差异无统计学意义(P>0.05),治疗后2周观察组患者的白细胞计数高于对照组(P<0.05)。结论扶正升白汤用于治疗肺癌患者化疗后白细胞减少疗效显著,可使患者的白细胞增多,使用安全,没有明显的不良反应,值得临床推广。
Objective To investigate the clinical efficacy of Fuzheng Shengbai decoction in the treatment of patients with lung cancer after leukopenia. Methods 50 patients with lung cancer were randomly divided into observation group and control group, 25 cases each. The control group was treated with reserpine and the observation group was treated with Fuzheng Shengbai Decoction. The clinical efficacy of the two groups was compared. Results Before treatment, the number of white blood cells in the observation group was (6.55 ± 1.89) × 109 / L and (5.28 ± 1.52) × 109 / L after 2 weeks of treatment, respectively; the control group was 6.47 ± 1.82 and 4.75 ± 1.10 ) × 109 / L. There was no significant difference in the number of white blood cells between the two groups before treatment (P> 0.05). The white blood cell count of the observation group was higher than that of the control group 2 weeks after treatment (P <0.05). Conclusion Fuzheng Shengbai Decoction for the treatment of patients with lung cancer after chemotherapy leukopenia significant effect, allowing patients with leukocytosis, safe use, no obvious adverse reactions, is worth clinical promotion.